# Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT04908566** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 124 (estimated)

## Conditions studied

- Locally Advanced Gastric Adenocarcinoma

## Interventions

- **DRUG:** PD-1 antibody combined with FOLFIRINOX regimen
- **DRUG:** PD-1 antibody combined with SOX program

## Key facts

- **NCT ID:** NCT04908566
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05
- **Primary completion:** 2023-08
- **Final completion:** 2028-08
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908566, "Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04908566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*